Recent studies have shown an association between the circulating A-FABP concentration and future cardiovascular disease in patients with end-stage renal disease [10], prevalent coronary heart disease [11], and acute coronary syndrome [12] as well as in a community-based cohort [13]. The gene discussed is FABP4; the disease is acute coronary syndrome.